Related references
Note: Only part of the references are listed.Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter?
K. C. Chang et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
An official ATS statement: Hepatotoxicity of antituberculosis therapy
Jussi J. Saukkonen et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Adverse events and treatment interruption in tuberculosis patients with and without HIV coinfection
R. A. M. Breen et al.
THORAX (2006)
Current concepts - Drug-related hepatotoxicity
VJ Navarro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management
M Nunez
JOURNAL OF HEPATOLOGY (2006)
High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis
AB Younossian et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Levofloxacin treatment of active tuberculosis and the risk of adverse events
F Marra et al.
CHEST (2005)
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection - A 7-year evaluation from a public health tuberculosis clinic
FF Fountain et al.
CHEST (2005)
Drug therapy - Drug metabolism and variability among patients in drug response
GR Wilkinson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?
M Kinzig-Schippers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberclosis treatment
M Sharifzadeh et al.
PHARMACOLOGICAL RESEARCH (2005)
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects
I Sanne et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin
SA Tasduq et al.
HEPATOLOGY RESEARCH (2005)
Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment
R van Hest et al.
CLINICAL INFECTIOUS DISEASES (2004)
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: Is it different than in HIV-uninfected persons?
FM Gordin et al.
CLINICAL INFECTIOUS DISEASES (2004)
An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment
FAD Kaona et al.
BMC PUBLIC HEALTH (2004)
Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities
Y Nishimura et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2004)
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease
P Gurumurthy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial
A Jindani et al.
LANCET (2004)
Medical progress: Drug-induced hepatotoxicity
WM Lee
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis
D Yee et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Cytochrome p450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis
YS Huang et al.
HEPATOLOGY (2003)
Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis
JE Stout et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis - Improved completion rates but more hepatotoxicity
L McNeill et al.
CHEST (2003)
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A multicenter clinical trial
RM Jasmer et al.
ANNALS OF INTERNAL MEDICINE (2002)
Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment
SK Sharma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism
SA Kliewer et al.
ENDOCRINE REVIEWS (2002)
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis
YS Huang et al.
HEPATOLOGY (2002)
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
GL Dean et al.
AIDS (2002)
Isoniazid is a mechanism-based inhibitor of cytochrome P-450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes
X Wen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy
S Pol et al.
JOURNAL OF VIRAL HEPATITIS (2002)
Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation
B Roy et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2001)
Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A
Z Desta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Idiosyncratic drug reactions: the reactive metabolite syndromes
SR Knowles et al.
LANCET (2000)
Isoniazid- and rifampicin-induced oxidative hepatic injury -: protection by N-acetylcysteine
S Attri et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2000)
Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection
WM Wong et al.
HEPATOLOGY (2000)
Share Paper
